Hong Kong · Delayed Price · Currency is HKD Hua Medicine (Shanghai) Earnings Call Transcripts
Fiscal Year 2026
-
Sales and revenue surged in the first half of 2026, with dorzagliatin showing strong growth and efficacy across patient segments. Profitability improved sharply, and the company is on track to reach break-even by year-end, supported by stable pricing, patent extensions, and robust R&D pipeline.
Fiscal Year 2025
-
Revenue grew 93% year-over-year to nearly RMB 500 million, driven by a 91% increase in sales volume and expanded market access. Gross profit margin improved, selling expenses dropped, and profitability was achieved in commercialization. Patent and NRDL price extensions support long-term growth.
-
Revenue more than doubled year-over-year in H1 2025, driven by Dorzagliatin's commercialization and operational efficiency, with gross margin rising to 54%. Confident in reaching RMB 1 billion sales by 2027, supported by global expansion and new product launches.
Fiscal Year 2024
-
Transitioned to full commercialization, ending Bayer partnership and driving dorzagliatin sales growth. Net sales surged nearly 200% early in 2025, with a strong cash position and plans to reach RMB 1 billion sales and break-even by 2027. Expanding into new markets and developing a second-generation GKA.